Therapeutic and Toxicological Evaluations of Cyclosporine A Microspheres as a Treatment Vehicle for Uveitis in Rabbits
Authors:
- 1 April 2006
- journal article
- research article
- Published by SAGE Publications in Journal of Ocular Pharmacology and Therapeutics
- Vol. 22 (2) , 121-131
Abstract
Aim: This study was undertaken to investigate the therapeutic efficacy and the toxicity of the intravitreal biodegradable poly(dl-lactide-co-glycolide)co-polymer microspheres containing cyclosporin A (CsA-PLGA-MS) on experimental uveitis in rabbits. Methods: CsA-PLGA-MS that had been prepared by a solvent evaporation approach were characterized for morphology, particle size, entrapment efficiency, and in vitro release profile of CsA-PLGA-MS. Therapeutic efficacy of the CsA-PLGA-MS was evaluated by scoring of the inflammation, aqueous leukocyte counting, aqueous protein determination, and histological examination in the experimental rabbits with artificial uveitis induced by the injection of lipopolysaccharide. The toxicity was investigated by slit-lamp examination, indirect ophthalmoscopy, and electroretinography (ERG) in the noninflamed rabbit eye. Results: The CsA-PLGA-MS were spherical in shape, with an average particle size of nearly 50 µm and an entrapment efficiency of more than 80%. The compositions of the formulation that was most effective in the in vivo studies included CsA, PLGA, and 3% Pluronic F68. In vitro released cyclosporine A from the optimized microspheres was approximately 25% during the 60-day incubation at 37°C. It was demonstrated that the intravitreal injection of the optimized CsA-PLGA-MS decreased significantly the severity of the inflammatory signs, cellular infiltrate, aqueous leukocyte counts, and protein levels in the eyes of experimental rabbits with uveitis, compared to other formulations. Also, the preparation did not cause obvious toxicity in the noninflamed eyes of rabbits, except that the ERG b-wave amplitude for the test eyes was reversibly depressed, compared to those of the control eyes at 2 weeks, which almost recovered at the end of 6 weeks. Conclusions: The CsA-PLGA-MS preparation might be useful in the treatment of patients with severe chronic posterior uveitis who cannot tolerate systemic or periocular therapy.Keywords
This publication has 16 references indexed in Scilit:
- Pharmacokinetic and Toxicity Study of an Intraocular Cyclosporine DDS in the Anterior Segment of Rabbit EyesInvestigative Ophthalmology & Visual Science, 2003
- Coinduction of Nitric Oxide Synthase and Arginine Metabolic Enzymes in Endotoxin-induced Uveitis RatsExperimental Eye Research, 2002
- Efficacy and safety of microspheres of cyclosporin A, a new systemic formulation, to prevent corneal graft rejection in ratsCurrent Eye Research, 2002
- Synthetic Lipid A-induced uveitis and endotoxin-induced uveitis—A comparative studyJapanese Journal of Ophthalmology, 1997
- Evaluation of a Delivery System Providing Long-term Release of CyclosporineArchives of Ophthalmology (1950), 1996
- Bioavailability of microsphere-entrapped cyclosporine A in the cornea and aqueous of rabbitsInternational Ophthalmology, 1993
- Ocular Penetration of Cyclosporine A in the Rat EyeArchives of Ophthalmology (1950), 1990
- Liposome-bound cyclosporine: Clearance after intravitreal injectionInternational Ophthalmology, 1988
- Local Cyclosporine Therapy for Experimental Autoimmune Uveitis in RatsArchives of Ophthalmology (1950), 1985
- Endotoxin-induced uveitis in rats as a model for human diseaseNature, 1980